PUMA BIOTECHNOLOGY, INC. financials

  1. Home
  2. Financials
  3. PBYI
PBYI CIK 0001401667

Source: EDGAR filings · Built 2026-06-02T03:47:23Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 41.73M 38.86M 26.87M -15.83M 20.65M 727.00K
EBITDA 48.24M 42.49M 44.16M 33.56M 12.60M -20.37M
Working Capital 81.43M 51.55M 56.80M 56.80M 30.44M 31.88M
Net Debt -937.00K 5.82M 29.25M 41.77M 58.42M 35.66M
Gross Margin 74.53% 72.06% 73.40% 75.84% 74.84% 82.51%
Operating Margin 16.33% 13.44% 13.85% 10.40% 0.51% -13.51%
Net Margin 13.62% 13.14% 9.16% 0.00% -11.51% -26.65%
Return on Equity (ROE) 23.87% 32.87% 40.40% 0.01% 1190.76% 1008.15%
Return on Assets (ROA) 14.38% 14.19% 9.37% 0.00% -12.85% -24.57%
Current Ratio 2.00× 1.54× 1.57× 1.73× 1.28× 1.28×
Debt-to-Equity 0.22× 0.81× 2.13× 5.46× -49.69× -20.32×
Effective Tax Rate 13.05% -25.63% 4.78% 99.56% -1.12% -0.35%
Cash Conversion Ratio 1.34× 1.29× 1.25× -7913.50× -0.71× -0.01×
Accruals Ratio -0.05× -0.04× -0.02× 0.07× -0.22× -0.25×
SBC % of Revenue 3.04% 3.58% 4.35% 5.19% 12.89% 16.25%
CapEx Coverage 588.76× 694.96× 192.92× — — 16.80×
Free Cash Flow Per Share $0.82 $0.79 $0.57 $-0.35 $0.51 $0.02

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 9.75× 4.92× 9.62× — — —
P/FCF 7.22× 3.85× 7.66× — 5.98× 557.61×
FCF Yield 13.85% 25.95% 13.05% — 16.71% 0.18%
EV / EBITDA 6.20× 3.66× 5.33× 7.09× 14.58× —
P/S 1.31× 0.65× 0.88× 0.86× 0.49× 1.83×
P/B 2.30× 1.63× 3.86× 9.07× — —

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 228.37M 230.47M 235.64M 228.03M 253.16M 225.11M
Cost of Goods and Services Sold 58.16M 64.40M 62.68M 55.09M 63.70M 39.37M
Research and Development Expense — — — — 71.87M 97.65M
Selling, General and Administrative Expense 70.85M 80.16M 89.93M 89.98M 116.29M 118.49M
Operating Expenses — — — — — 255.51M
Operating Income (Loss) 37.30M 30.97M 32.64M 23.72M 1.29M -30.40M
Income Tax Expense (Benefit) 4.67M -6.18M 1.08M 455.00K 324.00K 207.00K
Net Income (Loss) Attributable to Parent 31.11M 30.28M 21.59M 2.00K -29.13M -59.99M
Earnings Per Share, Basic $0.62 $0.62 $0.46 $0.00 $-0.72 $-1.52
Weighted Average Number of Shares Outstanding, Basic 50.01M 48.65M 47.13M 44.67M 40.64M 39.58M
Earnings Per Share, Diluted $0.61 $0.62 $0.45 $0.00 $-0.72 $-1.52
Weighted Average Number of Shares Outstanding, Diluted 50.65M 49.10M 47.55M 44.93M 40.64M 39.58M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 29.64M 69.22M 84.58M 76.20M 63.13M 85.29M
Assets, Current 162.69M 147.66M 156.19M 134.28M 140.02M 146.14M
Assets 216.30M 213.33M 230.53M 222.06M 226.59M 244.22M
Long-term Debt 22.68M 68.00M 102.00M 102.00M 102.00M 84.03M
Liabilities, Current 81.25M 96.11M 99.38M 77.48M 109.59M 114.25M
Long-term Debt, Excluding Current Maturities 0 21.72M 65.66M 98.31M 97.09M 84.03M
Liabilities 85.96M 121.21M 177.09M 200.45M 229.03M 250.17M
Stockholders' Equity Attributable to Parent 130.34M 92.13M 53.44M 21.61M -2.45M -5.95M
Common Stock, Shares, Outstanding 50.41M 49.11M 47.65M 46.35M 41.18M 40.09M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 41.80M 38.92M 27.01M -15.83M 20.65M 773.00K
Payments to Acquire Property, Plant, and Equipment 71.00K 56.00K 140.00K 0 0 46.00K
Net Cash Provided by (Used in) Investing Activities -36.19M -20.44M -19.13M 7.10M -10.88M 33.40M
Net Cash Provided by (Used in) Financing Activities -45.20M -33.85M 0 12.22M -31.93M -9.93M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PBYI CIK 0001401667), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

PVLA

Palvella Therapeutics, Inc.

APP

AppLovin Corp

GRAL

GRAIL, Inc.